


BMS-817399

Chemical Properties

CAS No. : 1202400-18-7
 Formula: C₂₃H₃₆ClN₃O₄
 Molecular Weight: 454
 Storage: Powder: -20°C for 3 years | In solvent: -80°C for 1 year
 Actual storage temperature shall be subject to the COA.



Biological Description

Description	BMS-817399 is an orally active antagonist of CCR1 with IC ₅₀ s of binding affinity and chemotaxis inhibition potencies and can be used in studies about rheumatoid arthritis.
Targets(IC ₅₀)	CCR

Solubility Information

Solubility	DMSO: 55 mg/mL (121.15 mM), Sonication is recommended. (< 1 mg/ml refers to the product slightly soluble or insoluble)
In vivo Formulation	10% DMSO+40% PEG300+5% Tween 80+45% Saline: 2 mg/mL (4.41 mM), Sonication is recommended. <i>Please add the solvents sequentially, clarifying the solution as much as possible before adding the next one. Dissolve by heating and/or sonication if necessary. Working solution is recommended to be prepared and used immediately. The formulation provided above is for reference purposes only. In vivo formulations may vary and should be modified based on specific experimental conditions.</i>

Preparing Stock Solutions

	1mg	5mg	10mg
1 mM	2.2026 mL	11.0132 mL	22.0264 mL
5 mM	0.4405 mL	2.2026 mL	4.4053 mL
10 mM	0.2203 mL	1.1013 mL	2.2026 mL
50 mM	0.0441 mL	0.2203 mL	0.4405 mL

Please select the appropriate solvent to prepare the stock solution, according to the solubility of the product in different solvents. Please use it as soon as possible.

Note: The dilution table applies only to solid products. For liquid products, please calculate the stock solution based on the stated concentration and/or density.

Reference

- Chen H, et al. Moisture-Induced Amorphous Phase Separation of Amorphous Solid Dispersions: Molecular Mechanism, Microstructure, and Its Impact on Dissolution Performance. *J Pharm Sci.* 2018 Jan;107(1):317-326.
- Khan JA, et al. Developing Adnectins that target SRC co-activator binding to PXR: a structural approach toward understanding promiscuity of PXR. *J Mol Biol.* 2015 Feb 27;427(4):924-42.
- Santella JB 3rd, et al. Discovery of the CCR1 antagonist, BMS-817399, for the treatment of rheumatoid arthritis. *J Med Chem.* 2014;57(18):7550-7564.

Inhibitor · Natural Compounds · Compound Libraries · Recombinant Proteins

This product is for Research Use Only · Not for Human or Veterinary or Therapeutic Use

Tel:781-999-4286 E_mail:info@targetmol.com Address:34 Washington Street,Wellesley Hills,MA 02481